Objective: T1 high-grade bladder cancer has a poor prognosis compared with other non-muscleinvasive bladder cancers. We investigated the clinical outcomes among patients with T1 highgrade bladder cancer to identify factors related to cancer recurrence and disease progression. Methods: We retrospectively reviewed the data of 148 patients who were diagnosed with T1 highgrade bladder cancer by transurethral resection from January 2001 to February 2015 at our institution. Clinicopathological factors were analyzed using univariate and multivariate analyses. Results: The median age and follow-up duration were 72 years and 45.4 months, respectively. Sixty-two patients (41.9%) had recurrence, 28 (18.9%) experienced progression and 13 (8.8%) died of bladder cancer. In the multivariate analysis, divergent differentiation was an independent factor related to recurrence (P = 0.0096, hazard ratio = 2.5), whereas a non-papillary tumor shape, divergent differentiation and presence of a residual tumor at the time of the second transurethral resection were independent factors related to progression (P = 0.0349, hazard ratio = 3.8; P = 0.0074, hazard ratio = 6.8 and P = 0.0449, hazard ratio = 4.1, respectively). There were no independent factors related to cancer-specific mortality. Divergent differentiation was the only independent factor associated with both recurrence and progression. In addition, patients with divergent differentiation had significantly worse recurrence-free survival and progression-free survival rates than did patients without divergent differentiation (log-rank P = 0.0009 and P = 0.0019, respectively). Conclusions: In this study, the presence of divergent differentiation was related to worse oncological outcomes in patients with T1 high-grade bladder cancer. Patients with divergent differentiation may require stringent follow-up and early cystectomy after recurrence to improve oncological outcomes.
Introduction
Bladder cancer is a common urologic malignancy; it is the 7th and 17th most common cancer in men and women, respectively (1) . Approximately 75% of all bladder cancers are non-muscle-invasive bladder cancers (NMIBCs) with pathological stages of Ta, Tis and T1 (1, 2) . Although NMIBCs have a relatively low progression rate and favorable cancer-specific survival (CSS) rate after standard management with transurethral resection of the bladder tumor (TUR-BT) with or without subsequent intravesical instillation therapy, T1 high-grade (T1-HG) bladder cancer has a worse prognosis than other NMIBCs with recurrence and progression rates as high as 23-78% and 5-49%, respectively (3) (4) (5) . These data suggest that a specific treatment strategy is needed to decrease the recurrence rate and improve the prognosis in patients with T1-HG NMIBC. The guidelines of the National Comprehensive Cancer Network and European Association of Urology recommend a second TUR to prevent staging errors and residual tumors. Bacillus Calmette-Guerin (BCG) intravesical therapy followed by a second TUR or immediate cystectomy is strongly recommended (6, 7) . BCG therapy is the most effective intravesical therapy to reduce recurrence and progression (5, 8, 9) . However,~40% of patients do not respond to BCG therapy (8) , because T1-HG bladder cancer has heterogeneous features. Immediate cystectomy is recommended for some patients, but cystectomy for all patients with T1-HG bladder cancer may be overtreatment and adversely affect quality of life. The identification of clinicopathological factors associated with cancer recurrence and disease progression is crucial to choose appropriate treatment strategies for patients with T1-HG bladder cancer. Previous reports have shown that tumor multiplicity, tumor size, the presence of concomitant carcinoma in situ (CIS) and female sex are risk factors for a poor prognosis (1, 4, 5) . Some reports have suggested that a nonpapillary tumor shape or the presence of divergent differentiation is a prognostic factor (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
In this study, we retrospectively reviewed several clinicopathological factors associated with clinical outcomes of patients with T1-HG bladder cancer. We also investigated risk factors related to cancer recurrence, disease progression and cancer-specific mortality in these patients.
Patients and methods

Patient information
In total, 148 patients who underwent TUR-BT and were pathologically diagnosed with T1-HG bladder cancer at Yamaguchi University Hospital from January 2001 to February 2015 were enrolled in this study. We retrospectively reviewed the patients' medical records. Patients with concomitant or a history of upper urinary tract urothelial cancer were excluded from the study. Written informed consent was obtained from all individuals enrolled in this study, which was approved by the institutional ethics committees of the Graduate School of Medicine, Yamaguchi University.
TUR-BT and instillation therapy
All patients underwent TUR-BT in a standard fashion by experienced urologists at our institution. Selected-site mucosal biopsy was routinely performed in all patients to identify concomitant CIS (20) . A second TUR was performed in patients who were candidates according to the European Association of Urology guideline (1,6) after 2008 and was carried out within 4-6 weeks after the initial TUR-BT. Mitomycin-C (30 mg per 40 ml saline) was administered as a single immediate instillation of postoperative chemotherapy, while the instillation was omitted when bladder perforation due to deep TUR-BT was suspected. Adjuvant intravesical chemotherapy was performed using mitomycin-C, adriamycin or pirarubicin. The schedule of adjuvant intravesical chemotherapy consisted of weekly administration for 6-26 weeks.
Two types of BCG strains were used: Immunobladder ® (80 mg per 40 ml saline, BCG Tokyo 172 strain) and ImmuCyst ® (81 mg per 40 ml saline, Connaught strain). These strains were instilled once weekly for 6-8 weeks. Maintenance BCG therapy was not routinely performed at our institution. 
Pathologic evaluation
Follow-up and end points
All patients were followed up with cystoscopic examination including washing urinary cytology every 3 months for the first 2 years after TUR-BT, every 4 months for the following year, every 6 months for the following 2 years and annually thereafter. Imaging studies including computed tomography and ultrasonography were carried out every 6 months for 3 years and annually thereafter. Recurrence was defined as the first tumor relapse with pathological confirmation regardless of the tumor stage. Progression was defined as either recurrence of disease with a tumor stage of T2 or higher in TUR specimens or distant metastases in imaging studies.
Statistical analysis
Categorical and continuous variables were compared with the chisquared test and the unpaired Student's t-test, respectively. Survival analysis was estimated by the Kaplan-Meier method and compared with the log-rank test. A Cox proportional hazards regression model was used in the multivariable analysis to identify the risk factors for recurrence and progression. Statistical analysis was performed using JMP software (Pro.11; SAS Institute, Inc., Cary, NC). P values were two-sided, and statistical significance was defined as P < 0.05 in all tests.
Results
The characteristics of 148 patients with T1-HG bladder cancer are shown in Table 1 . The median age and follow-up duration were 72 years and 45.4 months, respectively. Of the 148 patients, 121 (81.8%) had a papillary tumor shape and 27 (18.2%) had a nonpapillary tumor shape. Sixty-three patients (42.6%) had a solitary tumor, whereas 85 (57.4%) had multiple tumors. Seventeen patients (11.5%) had a divergent differentiation in UC. The most frequent divergent differentiation was glandular differentiation in 10 patients, followed by squamous differentiation in 5 patients and mixed divergent differentiation in 2 patients. The proportion of divergent differentiation in individual patients is shown in Table 2 . CIS was present in 61 patients (41.2%). Sixty-two patients (41.9%) had recurrence, 28 (18.9%) developed progression and 13 (8.8%) died of bladder cancer. Figure 2 shows the recurrence-free survival (RFS), progressionfree survival (PFS) and CSS using a Kaplan-Meier plot. The 5-year RFS, PFS and CSS were 54.0, 79.7 and 90.8%, respectively.
Eighty-four patients (58.7%) underwent a second TUR. Of these patients, 15 (17.9%) was absent of muscularis propria in initial TUR. Thirty-four (40.5%) had a residual tumor (Table 3) . Fifteen patients (17.9%) had a T1 residual tumor at the time of the second TUR. Two (2.4%) were upstaged. Radial cystectomy and bladder preservation with chemoradiation were performed in each patient. An absent muscle layer at the initial TUR and concomitant CIS were significantly associated with the presence of a residual tumor at the second TUR (P = 0.0076 and P = 0.0279, respectively), while the other factors were not. Adjuvant instillation therapy was performed in 63 patients, 14 (22.2%) of whom received an anticancer agent and 49 (77.8%) of whom received BCG instillation therapy.
We performed univariate and multivariate analyses using a Cox proportional hazards regression model to analyze the risk factors (including clinicopathological factors and postoperative treatments after the initial TUR) that were associated with recurrence, progression and cancer-specific mortality ( Table 4 ). The univariate analysis showed that divergent differentiation, immediate postoperative chemotherapy, a second TUR, adjuvant chemotherapy and BCG therapy were significantly associated with recurrence (P = 0.0032, P = 0.0002, P = 0.0008, P = 0.0236 and P = 0.0225, respectively). In the multivariate analysis, divergent differentiation was an independent risk factor for recurrence [hazard ratio (HR) = 2.4, 95% confidence interval (95% CI) = 1.2-4.5, P = 0.0133]. Regarding disease progression, the univariate analysis showed that a nonpapillary tumor shape, large tumor size, divergent differentiation, absence of the 'muscularis propria' at the initial TUR, presence of a residual tumor at the second TUR and immediate postoperative chemotherapy were significantly associated with progression (P = 0.0047, P = 0.0480, P = 0.0046, P = 0.0132, P = 0.0053 and P = 0.0109, respectively). Three of these six factors (non-papillary tumor shape, divergent differentiation and presence of residual tumor at the second TUR) were independently associated with progression in the multivariate analysis (HR = 3.8, 95% CI = 1.1-14.1, P = 0.0349; HR = 6.8, 95% CI = 1.7-29.2, P = 0.0075; and HR = 4.8, 95% CI = 1.0-20.3, P = 0.0455, respectively). The presence of divergent differentiation was the only independent factor related to both cancer recurrence and disease progression. Patients with divergent differentiation had a significantly worse RFS and PFS than did patients without divergent differentiation (log-rank P = 0.0009 and log-rank P = 0.0019, respectively) ( Fig. 3a and b) . The univariate analysis also showed that a large tumor size, absence of muscularis propria at the initial TUR, immediate postoperative chemotherapy and a second TUR were significantly associated with cancer-specific mortality (P = 0.0147, P = 0.0142, P = 0.0070 and P = 0.0165, respectively); however, these factors were not statistically significant in the multivariate analysis. Patients with divergent differentiation had a marginally worse CSS than did those without divergent differentiation (log-rank P = 0.1420) (Fig. 3c) . Patients with glandular differentiation have worse RFS, and PFS compared with those with pure UC (log-rank P = 0.0091 and log-rank P = 0.0245). There was a significant difference in the RFS, PFS and CSS between divergent differentiation with squamous differentiation and pure UC (log-rank P = 0.0245, log-rank P = 0.0280 and log-rank P = 0.0288, respectively), but no difference was found between squamous and glandular differentiation (Fig. 4) . In regard to the proportion of divergent Patients with glandular or squamous differentiation had a significantly worse PFS than did patients with pure UC (log-rank P = 0.0103 and 0.0280, respectively). No statistically significant difference in RFS was noted between variant histologic components (log-rank P = 0.7724).
(c) Patients with squamous differentiation had a significantly worse CSS than did patients with pure UC (log-rank P = 0.0288), while comparison with other cohorts showed no significant difference in CSS.
differentiation, there was no statistically significant difference related to prognosis (data are not shown).
Discussion
We recently reported that patients with upper tract UC (UTUC) with divergent differentiation had more biologically aggressive features than did patients with pure UTUC after radical nephroureterectomy (21) . UTUC is a potentially lethal disease and is histologically similar to urothelial bladder cancer. T1-HG bladder cancer is more difficult to cure than other NMIBCs, because T1-HG cancer has potentially aggressive features (1,3) . Several clinicopathological parameters have been regarded as powerful predictors of bladder cancer recurrence and progression. Similar to our recent results regarding UTUC (21), the present study showed that divergent differentiation is an independent risk factor for cancer recurrence. Additionally, the independent factors for disease progression were a non-papillary tumor shape, divergent differentiation and presence of a residual tumor at the second TUR, although no independent factors for cancer-specific mortality were found in our study. A history of bladder cancer, the number of tumors, the tumor size, the T category, the tumor grade, the presence of concomitant CIS and female sex are previously reported risk factors for recurrence and progression (1, 4, 5) . In previous reports confined to patients with T1-HG bladder cancer, risk factors included female sex, CIS in the prostatic urethra and recurrence within 3 months (1). Several previous reports suggested non-papillary tumor shape as a prognostic factor (10-12). Okajima et al. (11) reported that patients with non-papillary tumors had significantly worse CSS than did patients with papillary tumors. Park et al. (12) reported that non-papillary tumors were associated with the presence of lymphovascular invasion and CIS. Additionally, other reports showed that lymphovascular invasion was an independent prognostic factor for T1 bladder cancer (22, 23) . These data support our finding that a non-papillary tumor shape is a prognostic risk factor. The presence of a residual tumor at the second TUR was an independent predictor of progression in our study. Herr et al. (24) reported that patients with residual T1 cancer at the second TUR had a higher progression rate than did patients with T0/Tis/Ta cancer (82 vs. 19%, respectively), suggesting that patients with residual T1 tumors should be potential candidates for immediate cystectomy. Their report may support our finding that the presence of a residual tumor at the time of the second TUR was an independent prognostic risk factor. Divergent differentiation was the only risk factor related to both cancer recurrence and disease progression. Previous reports have shown that bladder cancer with divergent differentiation was associated with a worse prognosis than pure UC (13) (14) (15) (16) (17) (18) (19) , whereas there are conflicting reports about the impact of divergent differentiation on clinical outcomes (25) (26) (27) . Xylinas et al. (15) reported that divergent differentiation was significantly associated with recurrence and worse CSS in their univariate analysis. Soave et al. (18) also reported that the percentage of divergent differentiation in a specimen was associated with worse CSS in the univariate analysis. Several previous reports have suggested that the presence of divergent differentiation was associated with understaging (19, 20, 28) . The presence of divergent differentiation may be the predictor for upstaging at the time of radial cystectomy (19, 28) . These studies strongly suggest that the presence of divergent differentiation is associated with a higher likelihood of local disease advancement, metastasis and a poor prognosis than is pure UC. Most previous studies involved patients treated with cystectomy. Few reports to date have described the association of divergent differentiation with oncological outcomes in patients with T1-HG bladder cancer. In a study by Shapur et al. [16] , 22 patients with divergent differentiation treated with BCG therapy had significantly worse 5-year PFS with a shorter median time to progression than did patients with a pure UC counterpart, although RFS and CSS were not significantly different. Their data partially support our results that divergent differentiation was associated with a worse PFS. However, we observed no statistically significant difference in the CSS between patients with divergent differentiation and pure UC. This discrepancy may have resulted from heterogeneity of the divergent differentiation. Moreover, our sample size was small, and only 13 patients died from cancer. The small sample size may let the statistical power decreased. Thus, divergent differentiation did not associate with cancer-specific mortality. Nevertheless, this is the first study to demonstrate that divergent differentiation in patients with T1-HG bladder cancer is an independent predictor of cancer recurrence and disease progression based on a multivariate analysis.
The reason why divergent differentiation was associated with a worse prognosis in patients with bladder cancer remains unclear. Divergent differentiation implies heterogeneous pathological populations such as glandular differentiation, squamous differentiation or small cell carcinoma in combination with varying percentages of pure UC. The prognostic impact of a divergent differentiation tumor component is controversial (13) (14) (15) (16) (17) (18) (19) (25) (26) (27) . Interestingly, the efficacy of BCG therapy is likely to depend on the variant type of bladder cancer in a given patient. Several investigators have reported that patients with bladder cancer with glandular differentiation were successfully treated with BCG therapy (27, 29) . Glandular or squamous differentiation seems to be relatively less sensitive to chemotherapy and radiotherapy than is UC (13). Lynch et al. (30) showed that adjuvant chemotherapy was significantly effective for small cell carcinoma of the bladder. Our results suggest that a squamous component is likely to indicate a poorer prognosis than glandular differentiation, as shown in Figure 3 . Taken together with previous reports, our data indicate that variant histology with a squamous component might be a candidate for immediate cystectomy rather than BCG therapy in patients with T1-HG bladder cancer. Patients with variant histology should be more carefully observed than those without divergent differentiation. Further investigation is needed to assess the use of BCG therapy in patients with divergent differentiation.
In conclusion, this is the first study to show that divergent differentiation in UC is associated with worse oncological outcomes in patients with T1-HG bladder cancer than in those with pure UC based on a multivariate analysis. Patients with divergent differentiation require careful observation, and immediate cystectomy may be the best treatment option particularly for patients with a squamous differentiation component.
